AI Article Synopsis
- Immunotherapy shows potential for treating gliomas, but clinical trials haven't significantly improved patient survival rates.
- Preclinical models used for glioma research need to accurately reflect real-world characteristics like tumor behavior, genetic mutations, and immune system interactions.
- This review examines common preclinical models in glioma immunology, assessing their strengths and weaknesses, while also providing examples of how they've been used in research aimed at real-world applications.
Article Abstract
Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed features regarding glioma behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into the common preclinical models used in glioma immunology, discuss their advantages and disadvantages, and highlight examples of their utilization in translational research.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296936 | PMC |
| http://dx.doi.org/10.3390/curroncol30060428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!